InspireMD, Inc. (NSPR): Entry into a Material Definitive Agreement
InspireMD, Inc. (NSPR) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 InspireMD Announces Pricing of $37.5 Million Public Offering Miami, FL -- November 13, 2026 — InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the pricing
- Instrument
- common stock
- Shares
- 7,342,308 shares
- Gross proceeds
- $37.5 Million
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
The offering adds $37.5 M of capital but introduces up to 15% additional shares, likely diluting earnings per share and prompting short‑term price weakness.
Market read
Primary disclosure of a new capital raise for a micro‑cap biotech; relevant for short‑term traders and long‑term investors assessing dilution versus growth funding.
What to watch
Recall risk for the CGuard Prime system and existing cash burn may offset benefits of the raise.
Background
InspireMD (Nasdaq: NSPR) develops carotid stent systems and filed an 8‑K to disclose the pricing of its latest equity offering.
Ticker impact
InspireMD announced pricing of a $37.5 million public offering of common stock, pre‑funded warrants and common warrants.
downward pressure as market prices in dilution
New equity issuance of ~15% over‑allotment option signals supply increase; investors typically react with short‑term price decline.
Market effects
Medical‑device and biotech stocks may see heightened scrutiny on dilution risk.
US listed biotech sector could experience modest sell‑off pressure.
Limited to investors tracking small‑cap medical‑device issuers.
Counterpoint
The proceeds could fund R&D and accelerate product rollout, supporting a longer‑term upside.
Key entities
- companyInspireMD, Inc.
Medical‑device firm issuing new equity.
- underwriterLake Street Capital Markets
Sole book runner for the offering.

